AbbVie has plenty of cost-cutting room if Humira sales hit the skids: analyst

Some industry watchers foresee biosimilars gutting Humira sales not too far into the future, though maker AbbVie ($ABBV) disagrees. If that scenario does play out, though? The Illinois pharma has room to pare down its marketing expenses, according to one analyst. Report

Suggested Articles

If Pfizer wants Lorbrena to be a true follow-up to Xalkori, it has to win a first-line OK in ALK-positive lung cancer. And it just got closer.

Eylea sales dropped 4% to $1.11 billion amid the pandemic, but still beat expectations. And meanwhile, Regeneron's COVID antibody is advancing.

Johnson & Johnson inked a $10-per-dose vaccine supply deal with the U.S. for 100 million initial doses, with 200 million more available down the line.